- Home
- SOR vs RIGL Comparison
SOR vs RIGL Comparison
Compare SOR & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- RIGL
- Stock Information
- Founded
- SOR 1968
- RIGL 1996
- Country
- SOR United States
- RIGL United States
- Employees
- SOR N/A
- RIGL N/A
- Industry
- SOR Investment Managers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- RIGL Health Care
- Exchange
- SOR Nasdaq
- RIGL Nasdaq
- Market Cap
- SOR 348.7M
- RIGL 366.5M
- IPO Year
- SOR N/A
- RIGL 2000
- Fundamental
- Price
- SOR $41.63
- RIGL $17.15
- Analyst Decision
- SOR
- RIGL Buy
- Analyst Count
- SOR 0
- RIGL 5
- Target Price
- SOR N/A
- RIGL $36.80
- AVG Volume (30 Days)
- SOR 16.2K
- RIGL 253.6K
- Earning Date
- SOR 01-01-0001
- RIGL 03-04-2025
- Dividend Yield
- SOR 7.24%
- RIGL N/A
- EPS Growth
- SOR N/A
- RIGL N/A
- EPS
- SOR 6.50
- RIGL 0.99
- Revenue
- SOR N/A
- RIGL $179,278,000.00
- Revenue This Year
- SOR N/A
- RIGL $14.19
- Revenue Next Year
- SOR N/A
- RIGL $13.10
- P/E Ratio
- SOR $6.41
- RIGL $17.17
- Revenue Growth
- SOR N/A
- RIGL 54.71
- 52 Week Low
- SOR $36.41
- RIGL $7.48
- 52 Week High
- SOR $42.75
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- SOR 44.80
- RIGL 32.74
- Support Level
- SOR $41.27
- RIGL $19.81
- Resistance Level
- SOR $42.50
- RIGL $19.97
- Average True Range (ATR)
- SOR 0.78
- RIGL 1.04
- MACD
- SOR 0.02
- RIGL -0.31
- Stochastic Oscillator
- SOR 28.38
- RIGL 5.83
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.